ストックスクリーナーアプリを入手
1.20
2.56%
0.03
プレマーケット:
1.20
Fate Therapeutics Inc (FATE) 最新ニュース
Gains Recap: Can Fate Therapeutics Inc lead its sector in growthMarket Movers & Community Verified Watchlist Alerts - baoquankhu1.vn
Fate Therapeutics (NASDAQ:FATE) Shares Pass Above 50-Day Moving AverageWhat's Next? - MarketBeat
Fate Therapeutics (NASDAQ:FATE) Shares Pass Above 50-Day Moving Average – What’s Next? - Defense World
Nasdaq Moves: What is the dividend yield of Fate Therapeutics IncMarket Performance Recap & Expert Approved Trade Ideas - baoquankhu1.vn
Growth Report: What analysts say about Fate Therapeutics Inc stockJuly 2025 Catalysts & Expert-Curated Trade Recommendations - baoquankhu1.vn
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Fate Therapeutics, Inc. (NASDAQ:FATE) Given Consensus Rating of "Hold" by Analysts - MarketBeat
Fate Therapeutics, Inc. (NASDAQ:FATE) Given Consensus Rating of “Hold” by Analysts - Defense World
Loss Report: Can Fate Therapeutics Inc ride the EV waveVolume Spike & Free Expert Verified Stock Movement Alerts - baoquankhu1.vn
The Truth About Fate Therapeutics Inc: Is This Biotech Underdog About To Explode Or Implode? - AD HOC NEWS
Breaking Barriers: How 2026’s Top Clinical Leaders Are Disrupting Chronic Disease Markets - GlobeNewswire Inc.
Guidance Update: What analysts say about Fate Therapeutics Inc stock2025 Price Targets & Scalable Portfolio Growth Methods - baoquankhu1.vn
Fate Therapeutics (NASDAQ:FATE) Stock Price Crosses Above 50-Day Moving AverageHere's What Happened - MarketBeat
Fate Therapeutics (NASDAQ:FATE) Stock Price Crosses Above 50-Day Moving Average – Here’s What Happened - Defense World
Great week for Fate Therapeutics, Inc. (NASDAQ:FATE) institutional investors after losing 6.3% over the previous year - simplywall.st
Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2021 Financial Results - IT Business Net
Cindy Tahl Sells 10,589 Shares of Fate Therapeutics (NASDAQ:FATE) Stock - Defense World
Insider Selling: Fate Therapeutics (NASDAQ:FATE) Insider Sells 10,589 Shares of Stock - MarketBeat
Does Fate Therapeutics Inc. stock trade at a discount to peers2025 Sector Review & Expert-Curated Trade Recommendations - Улправда
Will Fate Therapeutics Inc. stock benefit from infrastructure spending2025 Market Overview & Fast Gain Stock Trading Tips - Улправда
Will Indaptus Therapeutics Inc. stock reach Wall Street targetsJuly 2025 Technicals & Entry Point Confirmation Alerts - Улправда
Can Fate Therapeutics Inc. stock beat market expectations this quarterNew Guidance & High Accuracy Swing Entry Alerts - Улправда
Will Fate Therapeutics Inc. stock sustain high P E ratiosJuly 2025 Selloffs & AI Powered Market Entry Ideas - Улправда
Why Fate Therapeutics Inc. stock could outperform in 20252025 Bull vs Bear & Comprehensive Market Scan Insights - Улправда
Trend Review: Why Fate Therapeutics Inc stock could outperform in 2025Layoff News & Technical Buy Zone Confirmation - Bộ Nội Vụ
Fate Therapeutics, Inc. (NASDAQ:FATE) Receives Consensus Recommendation of “Hold” from Brokerages - Defense World
Fate Therapeutics, Inc. (NASDAQ:FATE) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat
Fate Therapeutics reports new employee inducement awards under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(C)(4) - TradingView — Track All Markets
The Pipeline for iPSC-Derived Cell Therapeutics in 2026 - BioInformant
Fate Therapeutics (NASDAQ:FATE) Shares Pass Below Two Hundred Day Moving AverageHere's Why - MarketBeat
Who Are the Top 19 NK Cell Therapy Companies Globally? - Global Growth Insights
ETF Watch: Can Fate Therapeutics Inc stock beat market expectations this quarterTrade Exit Summary & Growth Oriented Trading Recommendations - moha.gov.vn
Companies Like Fate Therapeutics (NASDAQ:FATE) Could Be Quite Risky - Yahoo Finance
Is Fate Therapeutics Inc. stock positioned for long term growth2025 EndofYear Setup & Entry Point Confirmation Signals - Улправда
Will Fate Therapeutics Inc. stock keep outperforming rivalsEarnings Trend Report & Safe Swing Trade Setups - Улправда
Fate Therapeutics, Inc.(NasdaqGM: FATE) dropped from NASDAQ Biotechnology Index - marketscreener.com
Why hedge funds are buying Fate Therapeutics Inc. stockJuly 2025 Spike Watch & Long-Term Growth Plans - Улправда
Cell Therapy Technologies Market Top Players, Segments & Regional Trends by 2034 - Straits Research
Fate Therapeutics Inc (FATE) presents a great opportunity, but the stock is slightly overvalued - uspostnews.com
Healthy Upside Potential: Fate Therapeutics Inc (FATE) - setenews.com
Fate Therapeutics Inc Stock Analysis and ForecastMarket Profile Overview & Fast Profit Portfolio Plans - earlytimes.in
Fate Therapeutics reports positive lupus treatment data at ASH meeting - Investing.com
Fate Therapeutics reports positive lupus treatment data at ASH meeting By Investing.com - Investing.com Canada
Fate Therapeutics Reports Positive Clinical Updates for FT819 in Systemic Lupus Erythematosus and Introduces Next-Generation CAR T-Cell Programs at ASH Annual Meeting - Quiver Quantitative
Fate Therapeutics Presents Updated Phase 1 Clinical Data of FT819 Off-the-shelf CAR T-cell Product Candidate for Systemic Lupus Erythematosus and Preclinical Advances in Next-Generation Off-the-Shelf CAR T-cell Programs - The Manila Times
1.24%
0.19%
大文字化:
|
ボリューム (24 時間):